Published in Br J Cancer on February 01, 2000
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med (2003) 12.17
Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol (2009) 2.94
Epigenetic and genetic features of 24 colon cancer cell lines. Oncogenesis (2013) 2.02
Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut (2005) 1.87
Mismatch repair deficient colorectal cancer in the era of personalized treatment. Nat Rev Clin Oncol (2010) 1.62
Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications. Clin Cancer Res (2012) 1.57
EMAST is a Form of Microsatellite Instability That is Initiated by Inflammation and Modulates Colorectal Cancer Progression. Genes (Basel) (2015) 1.01
The role of chemotherapy in microsatellite unstable (MSI-H) colorectal cancer. Int J Colorectal Dis (2006) 0.94
Prognostic and predictive biomarkers: tools in personalized oncology. Mol Diagn Ther (2014) 0.92
MSH3 mismatch repair protein regulates sensitivity to cytotoxic drugs and a histone deacetylase inhibitor in human colon carcinoma cells. PLoS One (2013) 0.91
Methylated BNIP3 gene in colorectal cancer prognosis. Oncol Lett (2010) 0.83
Microsatellite instability in colorectal cancer. Radiol Oncol (2011) 0.82
Implications of mismatch repair-deficient status on management of early stage colorectal cancer. J Gastrointest Oncol (2015) 0.81
Pharmacogenomic profiling and pathway analyses identify MAPK-dependent migration as an acute response to SN38 in p53 null and p53-mutant colorectal cancer cells. Mol Cancer Ther (2012) 0.79
γ-Glutamyl hydrolase modulation and folate influence chemosensitivity of cancer cells to 5-fluorouracil and methotrexate. Br J Cancer (2013) 0.78
Role of Deficient Mismatch Repair in the Personalized Management of Colorectal Cancer. Int J Environ Res Public Health (2016) 0.75
Responsiveness of CPT-11 in respect to hMLH1 and hMSH2 protein expression in the primary colorectal cancer. Cancer Res Treat (2004) 0.75
RFPL4A increases the G1 population and decreases sensitivity to chemotherapy in human colorectal cancer cells. J Biol Chem (2015) 0.75
Participation of p53 protein in the cellular response to DNA damage. Cancer Res (1991) 16.00
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell (1993) 12.02
Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med (1990) 11.57
p53 status and the efficacy of cancer therapy in vivo. Science (1994) 6.72
Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol (1997) 3.08
BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines. Cancer Res (1997) 2.77
P-glycoprotein and multidrug resistance. Curr Opin Genet Dev (1996) 2.33
Association of p53 mutations with short survival in colorectal cancer. Gastroenterology (1994) 2.19
Determination of the replication error phenotype in human tumors without the requirement for matching normal DNA by analysis of mononucleotide repeat microsatellites. Genes Chromosomes Cancer (1998) 2.09
Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol (1995) 2.09
p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res (1994) 1.94
Microsatellite instability and the role of hMSH2 in sporadic colorectalcancer. Oncogene (1996) 1.89
p53 point mutation and survival in colorectal cancer patients. Cancer Res (1995) 1.85
Use of the polymerase chain reaction in the quantitation of mdr-1 gene expression. Biochemistry (1990) 1.83
An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. Proc Natl Acad Sci U S A (1998) 1.83
CD95 (APO-1/Fas)-mediated apoptosis in colon epithelial cells: a possible role in ulcerative colitis. Gastroenterology (1997) 1.81
Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst (1994) 1.79
Alternative genetic pathways in colorectal carcinogenesis. Proc Natl Acad Sci U S A (1997) 1.68
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol (1997) 1.67
Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res (1994) 1.59
Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res (1996) 1.55
Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res (1987) 1.53
Microsatellite instability at multiple loci in gastric carcinoma: clinicopathologic implications and prognosis. Gastroenterology (1996) 1.51
Prognostic significance of DNA replication errors in young patients with colorectal cancer. Ann Surg (1998) 1.42
Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity. J Natl Cancer Inst (1997) 1.38
Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. Cancer Res (1995) 1.36
Topoisomerase I inhibitors: review and update. Ann Oncol (1997) 1.30
Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res (1990) 1.28
Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol (1996) 1.27
Differences in the spectrum of spontaneous mutations in the hprt gene between tumor cells of the microsatellite mutator phenotype. Mutat Res (1996) 1.25
Apoptotic depletion of CD4+ T cells in idiopathic CD4+ T lymphocytopenia. J Clin Invest (1996) 1.25
Eukaryotic DNA topoisomerase I: genome gatekeeper and its intruders, camptothecins. Semin Oncol (1996) 1.20
On the role of DNA double-strand breaks in toxicity and carcinogenesis. Crit Rev Toxicol (1997) 1.19
Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients. Cancer Res (1996) 1.11
Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives. Biochemistry (1995) 1.08
Efficient screening of p53 mutations by denaturing gradient gel electrophoresis in colorectal tumors. Oncogene (1993) 1.07
Inverse correlation between RER+ status and p53 mutation in colorectal cancer cell lines. Oncogene (1996) 1.06
CPT-11 (irinotecan) in the treatment of colorectal cancer. Eur J Cancer (1995) 0.99
Camptothecin inhibits both the cleavage and religation reactions of eukaryotic DNA topoisomerase I. J Mol Biol (1992) 0.98
Distinct chromosomal alterations associated with TP53 status of LoVo cells under PALA selective pressure: a parallel with cytogenetic pathways of colorectal cancers. Oncogene (1999) 0.96
Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies. Ann Oncol (1996) 0.95
Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors. Br J Cancer (1998) 0.93
CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein. Br J Cancer (1998) 0.91
Determinants of CPT-11 and SN-38 activities in human lung cancer cells. Br J Cancer (1998) 0.91
CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile. Semin Oncol (1996) 0.88
Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats. Jpn J Cancer Res (1995) 0.87
Expression of genes that regulate Fas signalling and Fas-mediated apoptosis in colon carcinoma cells. Cell Death Differ (1998) 0.87
DNA mismatch repair in mammals: role in disease and meiosis. Curr Opin Genet Dev (1997) 0.86
Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma. J Clin Oncol (1997) 0.86
Specific interaction of camptothecin, a topoisomerase I inhibitor, with guanine residues of DNA detected by photoactivation at 365 nm. Biochemistry (1993) 0.84
Different p53 mutations produce distinct effects on the ability of colon carcinoma cells to become blocked at the G1/S boundary after irradiation. Oncogene (1996) 0.82
Inactivation of p53 in normal human cells increases G2/M arrest and sensitivity to DNA-damaging agents. Int J Cancer (1998) 0.82
Apoptosis induced in human colorectal carcinoma by anti-Fas antibody. Ann Surg Oncol (1997) 0.80
Overexpression of p53 mRNA in colorectal cancer and its relationship to p53 gene mutation. Br J Cancer (1997) 0.80
Microsatellite instability in primary and metastatic colorectal cancers. Int J Cancer (1995) 0.80
The microsatellite mutator phenotype of colon cancer cells is often recessive. Oncogene (1995) 0.79
[What's new about microsatellite instability significance in human carcinogenesis?]. Bull Cancer (1997) 0.79
2,6-Bis((3,4-dihydroxyphenyl)-methylene)cyclohexanone (BDHPC)-induced apoptosis and p53-independent growth inhibition: synergism with genistein. Biochem Biophys Res Commun (1997) 0.77
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature (2001) 33.12
Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature (1996) 5.44
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer (2001) 5.36
Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci U S A (1997) 5.24
Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res (2001) 4.19
Fracture incidence after 3 years of aromatase inhibitor therapy. Ann Oncol (2014) 3.18
The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res (2001) 3.02
[A new technic of analysis of the human karyotype]. C R Acad Sci Hebd Seances Acad Sci D (1971) 2.62
Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res (2001) 2.50
Restriction of ocular fundus lesions to a specific subgroup of APC mutations in adenomatous polyposis coli patients. Cell (1993) 2.31
Association of p53 mutations with short survival in colorectal cancer. Gastroenterology (1994) 2.19
Hepatitis C virus genotyping by means of 5'-UR/core line probe assays and molecular analysis of untypeable samples. Virus Res (1995) 2.14
[Trisomy 21 and superoxide dismutase-1 (IPO-A). Tentative localization of sub-band 21Q22.1]. Exp Cell Res (1976) 2.07
High resolution R- and G-banding on the same preparation. Hum Genet (1981) 1.94
BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer Group. Am J Hum Genet (1997) 1.91
[Staining of human chromosomes with acridine orange after treatment with 5 bromodeoxyuridine]. C R Acad Sci Hebd Seances Acad Sci D (1973) 1.89
STK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas. Am J Pathol (2001) 1.89
NSD3, a new SET domain-containing gene, maps to 8p12 and is amplified in human breast cancer cell lines. Genomics (2001) 1.85
Chromosomal evolution in primates: tentative phylogeny from Microcebus murinus (Prosimian) to man. Hum Genet (1979) 1.75
Alternative genetic pathways in colorectal carcinogenesis. Proc Natl Acad Sci U S A (1997) 1.68
The prevalence of colonic polyps in acromegaly: a colonoscopic and pathological study in 103 patients. J Clin Endocrinol Metab (1995) 1.68
A simple method for simultaneous R- or G-banding and fluorescence in situ hybridization of small single-copy genes. Cytogenet Cell Genet (1992) 1.64
Methionine dependency of malignant tumors: a possible approach for therapy. J Natl Cancer Inst (1990) 1.64
Detection of plasma tumor DNA in head and neck squamous cell carcinoma by microsatellite typing and p53 mutation analysis. Cancer Res (2000) 1.63
Systematic analysis of 95 reciprocal translocations of autosomes. Hum Genet (1978) 1.59
Mapping of single-copy DNA sequences on human chromosomes by in situ hybridization with biotinylated probes: enhancement of detection sensitivity by intensified-fluorescence digital-imaging microscopy. Proc Natl Acad Sci U S A (1989) 1.59
Wide metastatic spreading in infiltrating lobular carcinoma of the breast. Eur J Cancer (2004) 1.58
Active suppression of in vitro reactivity of spleen cells after BCG treatment. Immunology (1978) 1.55
Germ-line mutations in the first 14 exons of the adenomatous polyposis coli (APC) gene. Am J Hum Genet (1993) 1.53
TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. Gastroenterology (1994) 1.50
[Trisomy for the distal part of the short arm of the number 3 chromosome in 3 siblings. First example of chromosomal insertion: INS(7;3)(q 31;p 21 p 26)]. Ann Genet (1972) 1.50
Mutations in OGG1, a gene involved in the repair of oxidative DNA damage, are found in human lung and kidney tumours. Oncogene (1998) 1.49
Oncogenic mutations as predictive factors in colorectal cancer. Oncogene (2010) 1.45
Performance of office hysteroscopy and endometrial biopsy for detecting endometrial disease in women at risk of human non-polyposis colon cancer: a prospective study. Int J Gynecol Cancer (2008) 1.43
Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. Cancer Res (1993) 1.41
[The Dr phenotype: a study of threee cases with a ring D chromosome]. Ann Genet (1968) 1.41
[Pericentric inversion, inv(10), in a mother and aneusomy by recombination, inv(10), rec(10), in her son (author's transl)]. Cytogenet Cell Genet (1973) 1.40
Emergence and scattering of multiple neurofibromatosis (NF1)-related sequences during hominoid evolution suggest a process of pericentromeric interchromosomal transposition. Hum Mol Genet (1997) 1.40
p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. J Clin Oncol (2000) 1.39
RFLP identified by the anonymous DNA segment OL VII E10 at 18q21.3 (HGM no. D18S8). Nucleic Acids Res (1987) 1.38
High frequencies of inversions and translocations of chromosomes 7 and 14 in ataxia telangiectasia. Mutat Res (1980) 1.38
Constitutional balanced translocations in patients with solid tumors. Cancer Genet Cytogenet (1992) 1.38
Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol (1992) 1.37
Sequence of DNA replication in 277 R- and Q-bands of human chromosomes using a BrdU treatment. Chromosoma (1976) 1.36
[The mechanism of chromosome segmentation induced by BUDR (5-bromodeoxyuridine)]. Ann Genet (1974) 1.35
Screening for germ-line mutations in the NF2 gene. Genes Chromosomes Cancer (1995) 1.35
MYC activation associated with the integration of HPV DNA at the MYC locus in genital tumors. Oncogene (2006) 1.31
Detection of DNA amplification in 17 primary breast carcinomas with homogeneously staining regions by a modified comparative genomic hybridization technique. Genes Chromosomes Cancer (1994) 1.30
Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa"). Br J Cancer (2002) 1.29
Tumour suppressive properties of fibroblast growth factor receptor 2-IIIb in human bladder cancer. Oncogene (1999) 1.27
Physical mapping of human loci homologous to the chicken nov proto-oncogene. Oncogene (1992) 1.26
Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition pore. Oncogene (1999) 1.26
SOD2: a new type of tumor-suppressor gene? Int J Cancer (1992) 1.24
Identification of amplified DNA sequences in breast cancer and their organization within homogeneously staining regions. Genes Chromosomes Cancer (1995) 1.24
Desmoplastic small round cell tumors: results of a four-drug chemotherapy regimen in five adult patients. Cancer (1996) 1.23
[Giemsa-R-banding analysis of the trisomy 9p and report of a new case]. Humangenetik (1973) 1.23
[New system of chromosome banding: the T bands (author's transl)]. Chromosoma (1973) 1.23
Selective endoreduplication or branched chromosome? Exp Cell Res (1977) 1.22
[Chromosome 8 : complete trisomy and segmental trisomies]. Ann Genet (1977) 1.22
Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity. Oncogene (1999) 1.22
Culture of peripheral blood lymphocytes from sarcoidosis; response to mitogenic factor. Int Arch Allergy Appl Immunol (1971) 1.21
Genes occupy a fixed and symmetrical position on sister chromatids. Cell (1991) 1.20
Fibroblast-dependent tumorigenicity of cells in nude mice: implication for implantation of metastases. Cancer Res (1986) 1.19
Deletion proximal to DXS68 locus (L1 probe site) in a boy with Duchenne muscular dystrophy, glycerol kinase deficiency, and adrenal hypoplasia. Hum Genet (1988) 1.18
Determination of microsatellite instability, p53 and K-RAS mutations in hepatic metastases from patients with colorectal cancer: relationship with response to 5-fluorouracil and survival. Int J Cancer (2001) 1.18
[Four new cases of X-autosome translocation in man (author's transl)]. Humangenetik (1975) 1.17
Evidence of linkage of the inflammatory bowel disease susceptibility locus on chromosome 16 (IBD1) to ulcerative colitis. J Med Genet (1998) 1.17
Establishment and characterisation of a new tumorigenic cell line with a normal karyotype derived from a human breast adenocarcinoma. Br J Cancer (1990) 1.17
High glycolysis in gliomas despite low hexokinase transcription and activity correlated to chromosome 10 loss. Br J Cancer (1996) 1.17
Evidence for a correlation between late replication and autosomal gene inactivation in a familial translocation t(X;21). Hum Genet (1979) 1.17
The cell cycle of lymphocytes in Fanconi anemia. Hum Genet (1982) 1.16
[Study of progeny of individuals bearing a t(DqDq) translocation]. Ann Genet (1970) 1.15
The reliability of immunohistochemistry as a prescreening method for the diagnosis of hereditary nonpolyposis colorectal cancer (HNPCC)--results of an international collaborative study. Fam Cancer (2001) 1.13
Increased p53 protein content of colorectal tumours correlates with poor survival. Br J Cancer (1992) 1.13
[Partial trisomy 21 (21q21 - 21q22.2)]. Ann Genet (1976) 1.12
Cytogenetic study of breast cancer: clinicopathologic significance of homogeneously staining regions in 84 patients. Hum Pathol (1992) 1.12
Splenic modifications induced by cyclophosphamide in C3H/He, nude, and "B" mice. J Immunol (1977) 1.12
Polymorphisms and probable lack of mutation in the WAF1-CIP1 gene in colorectal cancer. Oncogene (1995) 1.12
DNA hypomethylation in breast cancer: an independent parameter of tumor progression? Cancer Genet Cytogenet (1997) 1.11
Proto-oncogene amplification and homogeneously staining regions in human breast carcinomas. Genes Chromosomes Cancer (1990) 1.11
Gliomas are driven by glycolysis: putative roles of hexokinase, oxidative phosphorylation and mitochondrial ultrastructure. Anticancer Res (1997) 1.10
Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance. Biochem Pharmacol (1992) 1.10
Mutational analysis of the PTEN gene in gliomas: molecular and pathological correlations. Int J Cancer (1999) 1.09
Deletion of band 13q21 is compatible with normal phenotype. Hum Genet (1985) 1.09
A minority of carcinoma cells producing acidic fibroblast growth factor induces a community effect for tumor progression. Proc Natl Acad Sci U S A (1994) 1.08
Cytogenetics of colorectal adenocarcinomas. Cancer Genet Cytogenet (1990) 1.08
[Translocation 46,XX, t(15; 21) (q13; q22,1) in the mother of 2 children with partial trisomy 15 and monosomy 21]. Ann Genet (1973) 1.08
Loss of alleles on chromosome 18 and on the short arm of chromosome 17 in polyploid colorectal carcinomas. Int J Cancer (1988) 1.08
Efficient screening of p53 mutations by denaturing gradient gel electrophoresis in colorectal tumors. Oncogene (1993) 1.07
Serological determination of hepatitis C virus genotype: comparison with a standardized genotyping assay. J Clin Microbiol (1997) 1.07
An unbalanced 4q-21q translocation identified by the R but not by the G and Q chromosome banding techniques. Ann Genet (1973) 1.07
Concerted nonsyntenic allelic losses in hyperploid hepatocellular carcinoma as determined by a high-resolution allelotype. Cancer Res (1997) 1.07
Human fibulin-4: analysis of its biosynthetic processing and mRNA expression in normal and tumour tissues. FEBS Lett (2001) 1.07
Simultaneous monitoring of P53 protein and DNA content of colorectal adenocarcinomas by flow cytometry. Int J Cancer (1990) 1.07